However, despite this success in the treatment of breast cancer, the efficacy of CDK4/6 inhibition is variable, with 10–20% of tumors primarily resistant and an additional 40% becoming resistant to these drugs within the first 2 years (Johnston et al., 2019; Hortobagyi et al., 2016). Here, CDK4 is linked to breast carcinoma.